Key result
Ivabradine monotherapy was successful in treating congenital junctional ectopic tachycardia in a pre-term neonate.
Why the study?
Ivabradine improves arrhythmia control in congenital JET when added to standard therapy, but had not been reported as monotherapy.
Does ivabradine monotherapy improve arrhythmia control in a pre-term neonate with congenital junctional ectopic tachycardia?
Case Report (n=1)
Does ivabradine monotherapy improve arrhythmia control in a pre-term neonate with congenital junctional ectopic tachycardia?
This case report provides the first evidence that ivabradine monotherapy can successfully treat congenital junctional ectopic tachycardia in a pre-term neonate.
May support ivabradine monotherapy in select neonates with congenital JET; leaves open confirmation in prospective trials.
Congenital JET (junctional ectopic tachycardia) is a rare and often difficult to treat tachyarrhythmia in young infants. The addition of Ivabradine to standard Congenital JET therapy has been shown to improve arrhythmia control. However, Ivabradine has not been reported as a single drug in the control of congenital JET. We report a pre-term neonate in whom Ivabradine monotherapy was successful in treating congenital JET.
No takes yet. Share an insight, caveat, or question.
Devaprasath et al. (2022) conducted a case report in Congenital junctional ectopic tachycardia (n=1). Ivabradine was evaluated on Treatment success. Ivabradine monotherapy was successful in treating congenital junctional ectopic tachycardia in a pre-term neonate.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: